Basic Information
Ninlaro
Regulatory Information
EMEA/H/C/003844
November 21, 2016
September 15, 2016
19
September 19, 2024
Company Information
Denmark
Takeda Pharma A/S Delta Park 45 2665 Vallensbaek Strand
Takeda Pharma A/S
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Ninlaro in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Ninlaro. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Ninlaro. For practical information about using Ninlaro, patients should read the package leaflet or contact their doctor or pharmacist.